Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9UI10
UPID:
EI2BD_HUMAN
Alternative names:
eIF-2B GDP-GTP exchange factor subunit delta
Alternative UPACC:
Q9UI10; Q53RY7; Q5BJF4; Q9BUV9; Q9UBG4; Q9UIQ9; Q9UJ95
Background:
The Translation initiation factor eIF-2B subunit delta, also known as eIF-2B GDP-GTP exchange factor subunit delta, plays a crucial role in protein synthesis. It catalyzes the exchange of eIF-2-bound GDP for GTP, a key step in the initiation of translation. Additionally, it is essential for viral replication in tracheal cells during influenza A virus infection.
Therapeutic significance:
Leukoencephalopathy with vanishing white matter 4, a severe brain disease, is linked to mutations affecting this protein. Understanding the role of Translation initiation factor eIF-2B subunit delta could open doors to potential therapeutic strategies for this debilitating condition.